ClinicalTrials.gg

Program

solizmestrocel

Also written as “human umbilical cord mesenchymal stem cells”, “Human umbilical cord mesenchymal stem cells” and “Human Umbilical Cord Mesenchymal Stem Cells Injection”.

Its studies are mostly in Liver Cirrhosis · Ischemic Stroke · Respiratory Distress Syndrome · Arthritis, Rheumatoid · Primary Ovarian Insufficiency, led by 22 companies.

Furthest: phase 2, since Apr 26, 201143 company-led studies, 20 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen Beike Bio-Technology60 open or runningphase 2since Apr 26, 2011Apr 26, 2011none ahead
Meridigen Biotech54 open or runningphase 1since Sep 17, 2019Sep 17, 2019none ahead
PT. Prodia Stem Cell Indonesia54 open or runningphase 2since Feb 20, 2020Feb 20, 2020Dec 2026phase 2 · NCT07439848
Shenzhen Hornetcorn Bio-technology40 open or runningphase 1since Nov 3, 2014Nov 3, 2014none ahead
Asia Cell Therapeutics (Shanghai)33 open or runningphase 2since May 25, 2023May 25, 2023Dec 31, 2026phase 1 · NCT05962762
Translational Biosciences30 open or runningphase 2since Oct 31, 2013Oct 31, 2013none ahead
Baylx21 open or runningphase 2since Jun 28, 2020Jan 30, 2019Dec 31, 2027phase 1 · NCT03828344
alliancells-bioscience-corporation-limited10 open or runningphase 2since Feb 22, 2012Feb 22, 2012none ahead
asia-stem-cell-regenerative-pharmaceutical-co-ltd11 open or runningno phasesince Sep 19, 2021Sep 19, 2021none ahead
beijing-tuohua-weiye-biotechnology-co-ltd11 open or runningphase 2since Feb 2, 2026Feb 2, 2026Dec 31, 2026phase 2 · NCT07413549
BOE Technology Group11 open or runningphase 1since May 22, 2026May 22, 2026Mar 30, 2028phase 1 · NCT07628933
bright-cell-inc11 open or runningphase 1since Aug 6, 2022Aug 6, 2022Jan 9, 2028phase 1 · NCT05494723
cellonis-biotechnology-co-ltd10 open or runningphase 1since Jun 10, 2010Jun 10, 2010none ahead
Cook Group11 open or runningphase 2since Aug 27, 2024Aug 27, 2024Oct 31, 2028phase 2 · NCT06579352
cytopeutics-sdn-bhd10 open or runningphase 2since Nov 15, 2020Nov 15, 2020none ahead
Ever Supreme Bio Technology10 open or runningphase 1since May 5, 2020May 5, 2020none ahead
guangzhou-saliai-stem-cell-science-and-technology-co-ltd10 open or runningphase 2since Jul 30, 2017Jul 30, 2017none ahead
jiangsu-topcel-kh-pharmaceutical-co-ltd11 open or runningphase 2since Mar 1, 2026Mar 1, 2026Mar 30, 2027phase 2 · NCT07452822
meribank-biotech-co-ltd11 open or runningphase 2since Jun 18, 2024Jun 18, 2024Dec 2026phase 2 · NCT06501066
shandong-qilu-stem-cells-engineering-co-ltd10 open or runningphase 2since May 6, 2018May 6, 2018none ahead
shanghai-life-science-technology10 open or runningphase 1since Mar 28, 2019Mar 28, 2019none ahead
Shenzhen Wingor Biotechnology11 open or runningphase 2since Jul 27, 2026Jul 27, 2026Sep 30, 2028phase 2 · NCT07775391

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 29 studies since Jun 10, 2010.

  1. Aug 1, 2021Phase 2 study in Ischemic StrokePT. Prodia Stem Cell Indonesia · NCT05008588 · 15 enrolled · Indonesia
  2. Sep 19, 2021asia-stem-cell-regenerative-pharmaceutical-co-ltd's first study: no phase study in Liver CirrhosisNew to asia-stem-cell-regenerative-pharmaceutical-co-ltdasia-stem-cell-regenerative-pharmaceutical-co-ltd · NCT05106972 · 30 planned · China
  3. Aug 6, 2022bright-cell-inc's first study: phase 1 study in POINew to bright-cell-incbright-cell-inc · NCT05494723 · 6 planned
  4. May 25, 2023Asia Cell Therapeutics (Shanghai)'s first study: phase 1 study in Spondylitis, AnkylosingNew to Asia Cell Therapeutics (Shanghai)Asia Cell Therapeutics (Shanghai) · NCT05962762 · 9 planned
  5. May 25, 2023Phase 2 study in Decompensated Liver CirrhosisAsia Cell Therapeutics (Shanghai) · NCT05948982 · 18 planned
  6. Jun 28, 2023Phase 2 study in Respiratory Distress SyndromePT. Prodia Stem Cell Indonesia · NCT07439848 · 15 planned · Indonesia
  7. Jul 26, 2023Phase 1 study in Respiratory Distress SyndromeAsia Cell Therapeutics (Shanghai) · NCT05983627 · 9 planned
  8. Jun 18, 2024meribank-biotech-co-ltd's first study: phase 2 study in Pathologic ProcessesNew to meribank-biotech-co-ltdmeribank-biotech-co-ltd · NCT06501066 · 66 enrolled · Taiwan
  9. Aug 27, 2024Cook Group's first study: phase 2 study in Muscular Dystrophy, DuchenneNew to Cook GroupCook Group · NCT06579352 · 35 enrolled · United States
  10. Jul 7, 2025Phase 2 study in Diabetic NephropathiesPT. Prodia Stem Cell Indonesia · NCT07396155 · 10 planned · Indonesia
  11. Feb 2, 2026beijing-tuohua-weiye-biotechnology-co-ltd's first study: phase 2 study in Decompensated Hepatitis B CirrhosisNew to beijing-tuohua-weiye-biotechnology-co-ltdbeijing-tuohua-weiye-biotechnology-co-ltd · NCT07413549 · 76 planned · China
  12. Mar 1, 2026jiangsu-topcel-kh-pharmaceutical-co-ltd's first study: phase 2 study in Arteriovenous Fistula StenosisNew to jiangsu-topcel-kh-pharmaceutical-co-ltdjiangsu-topcel-kh-pharmaceutical-co-ltd · NCT07452822 · 54 planned
  13. May 22, 2026BOE Technology Group's first study: phase 1 study in Ischemic StrokeNew to BOE Technology GroupBOE Technology Group · NCT07628933 · 35 planned · China
  14. Jul 27, 2026Shenzhen Wingor Biotechnology's first study: phase 2 study in Primary Ovarian InsufficiencyNew to Shenzhen Wingor BiotechnologyShenzhen Wingor Biotechnology · NCT07775391 · 59 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Pathologic Processesmeribank-biotech-co-ltd · NCT06501066
  2. Dec 2026Primary completion: phase 2 study in Respiratory Distress SyndromePT. Prodia Stem Cell Indonesia · NCT07439848
  3. Dec 31, 2026Primary completion: phase 2 study in Decompensated Hepatitis B Cirrhosisbeijing-tuohua-weiye-biotechnology-co-ltd · NCT07413549
  4. Dec 31, 2026Primary completion: phase 1 study in Spondylitis, AnkylosingAsia Cell Therapeutics (Shanghai) · NCT05962762

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 43 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07775391Primary Ovarian Insufficiency · China2RecruitingShenzhen Wingor BiotechnologySep 30, 202859
NCT07628933Ischemic Stroke · China1Not yet recruitingBOE Technology GroupMar 30, 202835
NCT07452822Arteriovenous Fistula Stenosis2Not yet recruitingjiangsu-topcel-kh-pharmaceutical-co-ltdMar 30, 202754
NCT07413549Decompensated Hepatitis B Cirrhosis · China2Recruitingbeijing-tuohua-weiye-biotechnology-co-ltdDec 31, 202676
NCT07396155Diabetic Nephropathies · Indonesia2RecruitingPT. Prodia Stem Cell IndonesiaJul 202710
NCT06579352Muscular Dystrophy, Duchenne · United States2Active, not recruitingCook GroupOct 31, 202835
NCT06501066Pathologic Processes · Taiwan2Active, not recruitingmeribank-biotech-co-ltdDec 202666
NCT05983627Respiratory Distress Syndrome1Not yet recruitingAsia Cell Therapeutics (Shanghai)Jun 30, 20259
NCT07439848Respiratory Distress Syndrome · Indonesia2RecruitingPT. Prodia Stem Cell IndonesiaDec 202615
NCT05962762Spondylitis, Ankylosing1Not yet recruitingAsia Cell Therapeutics (Shanghai)Dec 31, 20269
NCT05948982Decompensated Liver Cirrhosis2Not yet recruitingAsia Cell Therapeutics (Shanghai)Dec 31, 202618
NCT05494723POI1Not yet recruitingbright-cell-incJan 9, 20286
NCT05106972Liver Cirrhosis · China–Recruitingasia-stem-cell-regenerative-pharmaceutical-co-ltdDec 31, 202430
NCT05008588Ischemic Stroke · Indonesia2Active, not recruitingPT. Prodia Stem Cell IndonesiaMar 202615
NCT04914403Frailty · Taiwan1RecruitingMeridigen BiotechDec 20246
NCT04893174Osteoarthritis, Knee · Taiwan1RecruitingMeridigen BiotechSep 20246
NCT05016011Osteoarthritis, Knee · Malaysia2Completedcytopeutics-sdn-bhdMar 21, 202228
NCT04452097COVID-192WithdrawnBaylxJul 1, 20270
NCT04434768Stroke · Taiwan1CompletedEver Supreme Bio TechnologyJan 23, 202610
NCT04347967Respiratory Distress Syndrome · Taiwan1Not yet recruitingMeridigen BiotechSep 202418
NCT04315025Retinitis Pigmentosa · Indonesia2CompletedPT. Prodia Stem Cell IndonesiaJun 20, 201918
NCT04314687Cerebral Palsy · Indonesia2Active, not recruitingPT. Prodia Stem Cell IndonesiaJul 202678
NCT04206007Pulmonary Disease, Chronic Obstructive · Taiwan1UNKNOWNMeridigen BiotechDec 31, 20239
NCT04097652Ischemic Stroke · Taiwan1RecruitingMeridigen BiotechDec 31, 20239
NCT03902067Ventricular Dysfunction, Left · China1Withdrawnshanghai-life-science-technologyDec 31, 20250
NCT03828344Arthritis, Rheumatoid1Not yet recruitingBaylxDec 31, 202716
NCT03529136Decompensated Liver Cirrhosis2UNKNOWNshandong-qilu-stem-cells-engineering-co-ltdDec 31, 2019252
NCT03237442Ocular Corneal Burn · China2UNKNOWNguangzhou-saliai-stem-cell-science-and-technology-co-ltdDec 30, 2018100
NCT02790762Pneumoconiosis · China1UNKNOWNShenzhen Hornetcorn Bio-technologyJun 201710
NCT02652351Liver Cirrhosis · China1UNKNOWNShenzhen Hornetcorn Bio-technologyMay 201620
NCT02291926Cartilage Diseases · China1CompletedShenzhen Hornetcorn Bio-technologyJul 201620
NCT02283879Cerebral Hemorrhage · China1UNKNOWNShenzhen Hornetcorn Bio-technologyDec 201620
NCT02192749Autistic Disorder · Panama2CompletedTranslational BiosciencesAug 201720
NCT02034188Multiple Sclerosis · Panama2CompletedTranslational BiosciencesMar 201620
NCT01985464Arthritis, Rheumatoid · Panama2UNKNOWNTranslational BiosciencesDec 201920
NCT01742533Primary Ovarian Insufficiency · China2UNKNOWNShenzhen Beike Bio-TechnologyJun 201340
NCT01610440Muscular Dystrophy, Duchenne · China2UNKNOWNShenzhen Beike Bio-TechnologyMar 201315
NCT01547091Arthritis, Rheumatoid · China2UNKNOWNalliancells-bioscience-corporation-limitedOct 2014200
NCT01443689Burns · China2UNKNOWNShenzhen Beike Bio-TechnologyMar 201320
NCT01364246Multiple Sclerosis, Chronic Progressive · China2UNKNOWNShenzhen Beike Bio-TechnologyMar 201320
NCT01360164Spinocerebellar Degenerations · China2UNKNOWNShenzhen Beike Bio-TechnologyDec 201220
NCT01343511Autistic Disorder · China2CompletedShenzhen Beike Bio-TechnologyJun 201037
NCT01143168Diabetes Mellitus, Type 1 · China1UNKNOWNcellonis-biotechnology-co-ltdAug 201124

How it is read

Names in the registry

  • “human umbilical cord mesenchymal stem cells”, 6 entries
  • “Human umbilical cord mesenchymal stem cells”, 4 entries
  • “Human Umbilical Cord Mesenchymal Stem Cells Injection”, 3 entries
  • “UC-MSC”, 3 entries
  • “Umbilical Cord Mesenchymal Stem Cells”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.